Genmab A/S
GMABNASDAQHealthcare● Active
$24.80
$-0.35(-1.39%)
Market Cap$15.2B
P/E Ratio—
52W High$35.43
52W Low$20.225
Genmab A/S（GMAB）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · GMAB · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.96B | $7.84B | $5.64B | $7.04B | $3.98B |
| Depreciation & Amort. | $0.07B | $0.41B | $0.29B | $0.36B | $0.25B |
| Stock-Based Comp. | $0.00B | $0.72B | $0.59B | $0.44B | $0.31B |
| Change in Working Capital | $0.23B | ($1.59B) | $1.36B | ($1.93B) | ($0.77B) |
| Net Cash from Operations | $1.19B | $7.77B | $7.38B | $3.91B | $2.23B |
| Investing Activities | |||||
| Capital Expenditure | ($0.04B) | ($0.19B) | ($0.38B) | ($0.32B) | ($0.25B) |
| Purchases of Investments | ($1.00B) | ($8.64B) | ($10.91B) | ($9.70B) | ($15.62B) |
| Sales of Investments | $2.62B | $11.28B | $10.00B | $7.25B | $14.91B |
| Net Cash from Investing | ($5.65B) | ($9.91B) | ($1.28B) | ($2.76B) | ($0.96B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.43B) | ($3.99B) | ($0.56B) | ($0.91B) | ($0.45B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $5.23B | ($0.06B) | ($0.09B) | ($0.07B) | ($0.06B) |
| Net Cash from Financing | $4.79B | ($3.92B) | ($0.61B) | ($0.79B) | ($0.42B) |
| Free Cash Flow | |||||
| Free Cash Flow | $1.15B | $7.58B | $7.00B | $3.60B | $1.98B |
| FCF Margin %(computed) | 30.89% | 35.23% | 42.52% | 24.78% | 23.48% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Genmab A/S
关于Genmab A/S（GMAB）现金流量表
Genmab A/S 2025财年经营活动现金流$1.19B，自由现金流$1.15B（FCF利润率30.89%），资本支出($0.04B)。
常见问题
GMAB · 4 问Genmab A/S 2025财年自由现金流$1.15B，同比down84.8%。
GMAB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10